1 Top Penny Stock to Watch Now
This small-cap biotech is chasing a big breakthrough in 2026.
Barchart ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from BioXcel
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.
Benzinga ·
BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On?
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA).
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Read news from The Economist, FT, and more,
with one subscription
with one subscription
FDA Approves BioXcel's Igalmi - First Orally Dissolving Sublingual Film For Schizophrenia-Associated Agitation
The
Benzinga ·
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga ·
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga ·
BTAI: Final Countdown to April 5, 2022 PDUFA Date for BXCL501…
By David Bautz, PhD
NASDAQ:BTAI
READ THE FULL BTAI RESEARCH REPORT
Benzinga ·
BioXcel BXCL701 Combo Therapy Shows Encouraging Response Rates In Prostate Cancer
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype.
Benzinga ·
Coverage From
Benzinga
Barchart
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Nasdaq
22,848 stories
NYSE
19,912 stories
FDA
7,792 stories
EC
1,709 stories
Zacks SCR
184 stories
EMA
179 stories
Novartis
171 stories
Qatar Investment Authority
29 stories
argenx
28 stories
Oaktree
20 stories
NMPA
17 stories
BioXcel
12 stories
Atara
10 stories
IOVA
10 stories
Iovance
10 stories
Oaktree Capital Management
10 stories
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Topics
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
